TGFB1 and cancer: In this study, we attempted to investigate whether the combination treatment of T1-44, an inhibitor of PRMT5 methyltransferase activity, and Vactosertib, a TGF-β signaling inhibitor, was more effective in inhibiting cancer growth and metastasis and increasing survival rate than T1-44 or Vactosertib alone using human and mouse pancreatic cancer cells.